Microsoft word - seizures-treatment of resistant cases.docx
Marc Kent, DVM, DACVIM (Smal Animal and Neurology) Simon R. Platt, BVM&S, MRCVS, DACVIM (Neurology), DECVNANTIEPILEPTIC DRUGS FOR EMERGENCY DRUGS RESISTANT CASES Diazepam
Diazepam (Valium) is not a new drug and is widely used in the
Treatment Options
emergency treatment of seizures. Diazepam is often used in hos-
Several newer drugs are available for treating seizures. They can
pitalized animals, because it is given intravenously during a sei-
be used in combination with phenobarbital and potassium bromide
zure. Diazepam can also be administered into the nose or the
to improve seizure control in severely affected animals. These
rectum. Dogs with severe seizures can be given diazepam rectally
medications may also be tried as the sole treatment for seizures in
at home to reduce seizure severity and to try and prevent repeated
some cases, but their effectiveness as a sole therapy is unknown at
seizures. In dogs, the effect of diazepam is short lived, so the drug
present. Most of these newer drugs are also expensive. Once sei-
is not used for long-term management of seizures. On rare occa-
zure control has been achieved with any of these drugs, the dosage
sions, cats on oral diazepam can develop severe, often fatal, liver
of phenobarbital or potassium bromide can often be decreased.
damage, so oral administration of diazepam is done with caution
Levetiracetam
Levetiracetam (Keppra) is an antiepileptic drug that has few side
effects and may offer good seizure control in dogs. It is effective in
Follow-up Care
many cases refractory to other drugs. Levetiracetam is not elimi-
Once antiepileptic therapy is started, treatment commonly con-
nated from the body by the liver, so it can be used in animals with
tinues for life. Many antiepileptic drugs have side effects, so
liver disease. Levetiracetam comes as a tablet and is usually given
follow-up evaluations and close monitoring are required. At the
beginning of treatment, follow-up evaluations and telephone con-
Gabapentin
sultations are used to ensure the successful control of seizures via
Gabapentin (Neurotin) is also effective in many animals with seizures
appropriate dosing. Once the seizures are controlled, the animal
refractory to other drugs. The most common side effect is sedation.
is evaluated at least every 6 months. In addition to drug blood
Gabapentin is eliminated from the body by the liver and kidneys but
levels, other routine laboratory tests are used to monitor for side
has not yet been shown to cause liver disease. Gabapentin comes as
effects and to evaluate the animal’s general health. Always dis-
a capsule and is administered three times daily.
cuss any changes in medications with your veterinarian; it is dan-
Zonisamide
gerous to make dosage adjustments on your own. Even if side
Zonisamide (Zonegran) may be as effective as levetiracetam
effects occur, antiepileptic drugs should not be abruptly discon-
or gabapentin. It is well tolerated by dogs. Side effects include
tinued without consultation with a veterinarian. Discontinuation
decreased appetite, sedation, and incoordination. Allergic reac-
of these drugs is usually done gradually, under the direction of
tions, decreased tearing (dry eye), and blood disorders are poten-
tial side effects. Zonisamide is eliminated from the body by the liver, so is avoided in animals with liver disease. It comes as a tablet and is administered twice daily.
If you have other questions or concerns about this, or other health topics, please call
Copyright 2011 by Saunders, an imprint of Elsevier Inc. All rights reserved.
Actavis Performance Falls Short of Expectations Actavis’s 4Q results failed to live up to Research’s expectations. Total after-tax profit amoun-ted to EUR 14.6 million (m), while we had forecast EUR 17.1 m. The deviation is explained by a considerably lower EBITDA margin and write-offs resulting from impairment tests. Actavis’s total 4Q income was in line with predictions. Tota
A Comparison of 10 and 14 Days of Lansoprazole Triple Therapy for Eradication of Helicobacter pylori M. Brian Fennerty, MD; T. O. G. Kovacs, MD; R. Krause, MD; M. Haber, MD;A. Weissfeld, MD; N. Siepman, MD; P. Rose, MD Background: Data from large, multicenter, US studies in 84% (103/123) of those receiving 10-day triple therapydetermining the efficacy of triple therapy for the eradi-by